EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical

A Long but Worthwhile Wait for Vitiligo Treatments

The drug development landscape for vitiligo is sparse despite its social impact on individuals irrespective of race, ethnicity, or gender. Sometimes dubbed a “cosmetic condition,” years of research suggest vitiligo is an autoimmune disorder that could be triggered by an event (e.g., sunburn, illness, stress) or linked to specific genes. Jaime Polychrones at Clarivate explores more about the lack of treatments that are approved by the US Food and Drug Administration (FDA) for repigmentation of vitiligo lesions.

Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18